Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Aug 5, 2019

Provention Bio Announces Breakthrough Therapy Designation for Teplizumab (PRV-031) for the Prevention or Delay of Clinical Type 1 Diabetes in At-Risk Individuals
Jul 29, 2019

Sanofi delivered solid growth in Q2 2019
- Photos 4
Jul 10, 2019

FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma
Jun 26, 2019

FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis

* First biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP)
Jun 13, 2019

Provention Bio Announces Termination of Public Offering of Common Stock

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.